Mat Isa, Nur ‘Ayuni (2021) Evaluation of Efficacy and Safety of Herbal Medicine in the Treatment of Inflammatory Bowel Disease (IBD) via Systematic Review and Meta-analysis. [Project Paper] (Submitted)
![[img]](http://psaspb.upm.edu.my/style/images/fileicons/text.png) |
Text
FPSK2 2021 7.pdf Download (4MB) |
Abstract
Inflammatory bowel disease (IBD) and its persistent rising rate of prevalence has been regarded as a global healthcare issue and cause of increasing disease incidence in the world. This means that the number of patient are rising and expenses on public health system are also rising. Recently, herbal medicines have been used as an alternative to drug therapies. Synthetic drugs have been shown to cause adverse side effects and some to the extent of suppressing the immune system. In addition, herbalderived medicines can treat symptoms such as diarrhea, bloody stool, mucus and abdominal pain effectively. However, scientific evidences to support the efficacy and safety for the use of herbal medicines in the treatment of IBD are limited. Objectives: The purpose of this systematic review and meta-analysis is to evaluate the efficacy and safety for the use of herbal medicine in the treatment of IBD. Methodology: Studies of randomized controlled trial (RCT) and cohort research articles related to the use of herbal medicine in treating IBD patient were identified from three databases – PubMed, Sciencedirect and Scopus starting from 25th November 2020. The quality of studies was assessed by using standard quality assessment criteria Alberta Heritage Foundation for Medical Research (AHFMR). Total of 7 and 5 eligible studies were then subjected to systematic review and meta-analysis respectively. Results: Five studies describing the outcome of herbal medicine were identified, 3 studies of Crohn’s disease (CD) and 2 studies on ulcerative colitis (UC). Meta-analysis comparing the efficacy and safety of herbal medicine in the treatment of IBD from experimental and placebo groups revealed a non-significant difference studies (odds ratio, 1.26; 95% confidence interval [CI], 0.53-3.01; p=0.60) of achieving clinical remission in CD after treated with herbal medicine. In UC studies, there was a significant difference (odds ratio, 25.70; 95% confidence interval [CI] 7.10-114.67; p=0.001) in the clinical remission of both groups when treated with herbal medicine. The heterogeneity between the studies was not significant. Discussion: Herbal medicines identified from the systematic review and meta-analysis on CD (3 studies) are cannabis, Cannabidiol (CBD) and mastia (Pistacia lentiscus). In UC,curcumin (Curcuma longa) and Qing-Dai (Indigo naturalis) were identified. With exception of curcumin and Qing-Dai, the rate of clinical remission was not significant between experimental and placebo groups, and this may be due to small sample in the studies. In addition, no adverse effects were observed from the treatment. In contrast, the clinical remission rate in UC studies was higher in experimental groups. However, there are only 2 studies included in the synthesis of data in UC and thus, more studies are needed significant different (p = 0.001) effect between experimental and placebo group in the treatment of UC where there is higher rate of clinical remission. Thus, herbal medicine may be a therapeutic approach in the treatment of UC.
| Item Type: | Project Paper |
|---|---|
| Faculty: | Faculty of Medicine and Health Science |
| Depositing User: | Ms. Nor Safa'aton Saidin |
| Date Deposited: | 22 Aug 2023 07:47 |
| Last Modified: | 22 Aug 2023 07:47 |
| URI: | http://psaspb.upm.edu.my/id/eprint/1002 |
Actions (login required)
 |
View Item |